Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Scrip Asks...What Does 2019 Hold For Biopharma? Part 3: Pricing, Reimbursement And Market Access

Jan 15 2019

• By Eleanor Malone and Joseph Haas

2019 2018 Perspectives

Related Content

US Drug Pricing: What A Difference A Year Makes

Jan 02 2019

Hemophilia Seen As Good Testing Ground For Commercializing Gene Therapy

Oct 09 2018

Amgen Drops Repatha List Price 60% To Cut Medicare Co-Pays And Boost Use

Oct 25 2018

Part B's Foreign Price Bench-marking Will Only Hurt Bad Negotiators, HHS's Azar Argues

Oct 26 2018

Cell And Gene Therapies Test New Waters In Pricing And Reimbursement

Oct 06 2018

Cross-Country Collaborations, Business As Usual?

Dec 10 2018

Pharma: Be Prepared For Tougher Price Negotiations For IO Combos And Expansions In Europe

Dec 06 2018

Related Companies

Sutro Biopharma, Inc.

EyePoint Pharmaceuticals, Inc.

Amgen, Inc.

Athersys, Inc.

Cyclacel Pharmaceuticals, Inc.

Amarin Corp plc

Eisai Co., Ltd.

Spark Therapeutics, Inc.

Vertex Pharmaceuticals Incorporated

Biogen, Inc.

Genetix Biotherapeutics

BioMarin Pharmaceutical Inc.

Halozyme Therapeutics, Inc.

Bayer AG

ViiV Healthcare

Gilead Sciences, Inc.

Agendia

Additional Topics

Pricing Debate Pricing Strategies Reimbursement Market Access Scrip Asks BioPharmaceutical

More from Scrip Asks

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window